3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
7
Completed
7
Active not recruiting
2
Unknown
1
Terminated
1
Suspended
1
Available
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Interventions
Specimen Handling
5
Nivolumab
3
Biopsy
3
Magnetic Resonance Spectroscopy
2
Docetaxel
2
talazoparib
1
romidepsin
1
pembrolizumab
1
olaparib
1
imisopasem manganese
1
gallium 68 PSMA-11
1
durvalumab
1
balstilimab
1
aldesleukin
1
abivertinib
1
abiraterone
1
abarelix
1
Watchful Waiting
1
Standard of Care
1
Radiosurgery
1
Practice Guidelines as Topic
1
Palliative Care
1
Paclitaxel
1
Observation
1
N-acetylcochinol-O-phosphate
1
Mental Status and Dementia Tests
1
Menogaril
1
Magnetic Resonance Imaging
1
Ketones
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Suspended
×
talazoparib
×
Genitourinary
×
Clear all
NCT05425862
2023-12-11
REPAIR
Peter MacCallum Cancer Centre, Australia
Phase 1
Suspended
48 enrolled